(VIANEWS) – HighPeak Energy (HPK), First Community Bankshares (FCBC), Cathay General Bancorp (CATY) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. HighPeak Energy (HPK)
190.1% sales growth and 25.9% return on equity
HighPeak Energy, Inc., an independent oil and natural gas company, engages in the acquisition, exploration, development, and production of oil, natural gas, and natural gas liquids reserves in the Midland Basin in West Texas. As of December 31, 2020, the company had approximately 22,515 MBoe of proved reserves. HighPeak Energy, Inc. was founded in 2019 and is headquartered in Fort Worth, Texas.
Earnings Per Share
As for profitability, HighPeak Energy has a trailing twelve months EPS of $0.13.
PE Ratio
HighPeak Energy has a trailing twelve months price to earnings ratio of 165.19. Meaning, the purchaser of the share is investing $165.19 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.9%.
Volume
Today’s last reported volume for HighPeak Energy is 93892 which is 62.29% below its average volume of 249042.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 148.6% and 244%, respectively.
2. First Community Bankshares (FCBC)
17% sales growth and 10.98% return on equity
First Community Bankshares, Inc. operates as the financial holding company for First Community Bank that provides various banking products and services. It offers demand deposit accounts, savings and money market accounts, certificates of deposit, and individual retirement arrangements; commercial, consumer, and real estate mortgage loans, as well as lines of credit; various credit and debit cards, and automated teller machine card services; and corporate and personal trust services. The company also provides wealth management services, including trust management, estate administration, and investment advisory services; and investment management services. It serves individuals and businesses across various industries, such as education, government, and health services; coal mining and gas extraction; retail trade; construction; manufacturing; tourism; and transportation. As of December 31, 2021, the company operated 49 branches, including 17 branches in West Virginia, 23 branches in Virginia, 7 branches in North Carolina, and 2 branches in Tennessee. First Community Bankshares, Inc. was founded in 1874 and is headquartered in Bluefield, Virginia.
Earnings Per Share
As for profitability, First Community Bankshares has a trailing twelve months EPS of $2.4.
PE Ratio
First Community Bankshares has a trailing twelve months price to earnings ratio of 11.38. Meaning, the purchaser of the share is investing $11.38 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.98%.
Volume
Today’s last reported volume for First Community Bankshares is 4654 which is 79.93% below its average volume of 23196.
Yearly Top and Bottom Value
First Community Bankshares’s stock is valued at $27.33 at 20:22 EST, way under its 52-week high of $39.39 and higher than its 52-week low of $25.84.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 5.5% and positive 17.7% for the next.
3. Cathay General Bancorp (CATY)
10.9% sales growth and 14.66% return on equity
Cathay General Bancorp operates as the holding company for Cathay Bank that offers various commercial banking products and services to individuals, professionals, and small to medium-sized businesses in the United States. The company offers various deposit products, including passbook accounts, checking accounts, money market deposit accounts, certificates of deposit, individual retirement accounts, and public funds deposits. It also provides loan products, such as commercial mortgage loans, commercial loans, small business administration loans, residential mortgage loans, real estate construction loans, and home equity lines of credit, as well as installment loans to individuals for household, and other consumer expenditures. In addition, the company offers trade financing, letter of credit, wire transfer, forward currency spot and forward contract, traveler's check, safe deposit, night deposit, social security payment deposit, collection, bank-by-mail, drive-up and walk-up window, automatic teller machine, Internet banking, investment, and other customary bank services, as well as securities and insurance products. As of March 1, 2022, it operated 31 branches in Southern California, 16 branches in Northern California, 10 branches in New York, four branches in Washington, two branches in Illinois, and two branches in Texas, as well as one branch each in Maryland, Massachusetts, Nevada, and New Jersey, and Hong Kong; and a representative office each in Beijing, Taipei, and Shanghai. The company was founded in 1962 and is headquartered in Los Angeles, California.
Earnings Per Share
As for profitability, Cathay General Bancorp has a trailing twelve months EPS of $4.86.
PE Ratio
Cathay General Bancorp has a trailing twelve months price to earnings ratio of 7.61. Meaning, the purchaser of the share is investing $7.61 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.66%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 23.7%, now sitting on 775.97M for the twelve trailing months.
Moving Average
Cathay General Bancorp’s worth is way under its 50-day moving average of $42.57 and way under its 200-day moving average of $42.20.
Sales Growth
Cathay General Bancorp’s sales growth is 17.3% for the ongoing quarter and 10.9% for the next.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 33.3% and 11%, respectively.
4. Acadia Healthcare Company (ACHC)
9.9% sales growth and 10.21% return on equity
Acadia Healthcare Company, Inc. develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities, and outpatient behavioral healthcare facilities to serve the behavioral health and recovery needs of communities in the United States and Puerto Rico. The company operates acute inpatient psychiatric facilities, which cares to stabilize patients that are either threat to themselves or 24-hour observation, daily intervention, and monitoring by psychiatrists; and specialty treatment facilities, including residential recovery and eating disorder facilities, and comprehensive treatment centers that provide continuum care for adults with addictive disorders and co-occurring mental disorders. It also provides residential treatment centers, which treat patients with behavioral disorders in a non-hospital setting, including outdoor programs; and offer therapeutic placement for children and adolescents with emotional disorders. As of February 28, 2022, it operated a network of 228 behavioral healthcare facilities with approximately 10,500 beds. Acadia Healthcare Company, Inc. was founded in 2005 and is headquartered in Franklin, Tennessee.
Earnings Per Share
As for profitability, Acadia Healthcare Company has a trailing twelve months EPS of $2.86.
PE Ratio
Acadia Healthcare Company has a trailing twelve months price to earnings ratio of 23.9. Meaning, the purchaser of the share is investing $23.9 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.21%.
5. AdaptHealth Corp. (AHCO)
7.9% sales growth and 3.46% return on equity
AdaptHealth Corp., together with its subsidiaries, provides home healthcare equipment, medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; home medical equipment (HME) to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME medical devices and supplies on behalf of chronically ill patients with diabetes care, wound care, urological, ostomy, and nutritional supply needs. It serves beneficiaries of Medicare, Medicaid, and commercial payors. The company is headquartered in Plymouth Meeting, Pennsylvania.
Earnings Per Share
As for profitability, AdaptHealth Corp. has a trailing twelve months EPS of $0.33.
PE Ratio
AdaptHealth Corp. has a trailing twelve months price to earnings ratio of 41. Meaning, the purchaser of the share is investing $41 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.46%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 9.5%, now sitting on 2.97B for the twelve trailing months.
6. Clearwater Paper Corporation (CLW)
7.5% sales growth and 8.49% return on equity
Clearwater Paper Corporation produces and sells private label tissue and bleached paperboard products in the United States and internationally. The company operates through two segments, Consumer Products, and Pulp and Paperboard. The Consumer Products segment manufactures and sells a line of at-home tissue products, including bath tissues, paper towels, facial tissues, and napkins; recycled fiber value grade products; and away-from-home products and parent rolls. This segment sells its products to retailers and wholesale distributors, including grocery, drug, mass merchants, and discount stores. The Pulp and Paperboard segment manufactures and markets bleached paperboard, folding cartons, liquid packaging, cups and plates, blister and carded packaging, top sheet and commercial printing grades and softwood pulp products, as well as offers custom sheeting, slitting and cutting of paperboard. It sells its products to packaging converters, folding carton converters, merchants, and commercial printers. Clearwater Paper Corporation was incorporated in 2005 and is headquartered in Spokane, Washington.
Earnings Per Share
As for profitability, Clearwater Paper Corporation has a trailing twelve months EPS of $2.64.
PE Ratio
Clearwater Paper Corporation has a trailing twelve months price to earnings ratio of 12.69. Meaning, the purchaser of the share is investing $12.69 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.49%.
Volume
Today’s last reported volume for Clearwater Paper Corporation is 42088 which is 64.96% below its average volume of 120131.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 67% and 76.6%, respectively.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Clearwater Paper Corporation’s EBITDA is 0.52.
Sales Growth
Clearwater Paper Corporation’s sales growth is 12.9% for the present quarter and 7.5% for the next.
7. Amphastar Pharmaceuticals (AMPH)
7.1% sales growth and 16.51% return on equity
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Earnings Per Share
As for profitability, Amphastar Pharmaceuticals has a trailing twelve months EPS of $0.03.
PE Ratio
Amphastar Pharmaceuticals has a trailing twelve months price to earnings ratio of 1213.67. Meaning, the purchaser of the share is investing $1213.67 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.51%.
Volume
Today’s last reported volume for Amphastar Pharmaceuticals is 74840 which is 69.59% below its average volume of 246159.
Yearly Top and Bottom Value
Amphastar Pharmaceuticals’s stock is valued at $36.41 at 20:22 EST, way under its 52-week high of $44.46 and way higher than its 52-week low of $26.76.
Previous days news about Amphastar Pharmaceuticals(AMPH)
- According to Zacks on Thursday, 30 March, "The bottom line of Amphastar Pharmaceuticals outpaced estimates in all the last four quarters, the average surprise being 35%. "
